Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.38)
# 1,185
Out of 4,345 analysts
432
Total ratings
43.8%
Success rate
9.2%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Initiated Coverage: Buy | $14 | $12.85 | +8.95% | 1 | May 22, 2026 | |
| TNGX Tango Therapeutics | Maintained: Buy | $20 → $30 | $19.65 | +52.67% | 7 | May 15, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | $39 → $45 | $15.79 | +184.99% | 3 | May 14, 2026 | |
| UPB Upstream Bio | Maintained: Buy | $51 → $50 | $8.26 | +505.33% | 2 | May 14, 2026 | |
| ERAS Erasca | Maintained: Buy | $28 → $26 | $12.47 | +108.50% | 4 | May 12, 2026 | |
| STRO Sutro Biopharma | Initiated Coverage: Buy | $50 | $29.69 | +68.41% | 1 | Apr 30, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $140 → $185 | $153.00 | +20.92% | 15 | Apr 24, 2026 | |
| CLYM Climb Bio | Initiated Coverage: Buy | $18 | $11.96 | +50.50% | 1 | Apr 15, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $53 → $84 | $72.51 | +15.85% | 3 | Apr 14, 2026 | |
| APGE Apogee Therapeutics | Maintained: Buy | $105 → $110 | $77.75 | +41.48% | 8 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $10.37 | +150.72% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $17.47 | +71.72% | 26 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $81.70 | - | 2 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $31.65 | +51.66% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $18 | $21.58 | -16.59% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.5 | $2.98 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $38 | $7.73 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.25 | $3.81 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $53 | $68.65 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4.75 → $4.25 | $7.89 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $1.81 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 → $6 | $4.37 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $45 | $13.24 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $38 | $50.03 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $110 | $133.69 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $1.07 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $15 | $11.31 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $11.39 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $19 | $1.36 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $2.31 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.87 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $1.66 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $4.78 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $1.47 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $8.54 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 → $26 | $31.32 | n/a | 24 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $2.46 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1.75 | $2.40 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $26.87 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.44 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $4 | $16.91 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $36 | $12.72 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $2.15 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $18 | $2.44 | n/a | 4 | Apr 7, 2020 |
Q32 Bio
May 22, 2026
Initiated Coverage: Buy
Price Target: $14
Current: $12.85
Upside: +8.95%
Tango Therapeutics
May 15, 2026
Maintained: Buy
Price Target: $20 → $30
Current: $19.65
Upside: +52.67%
Avalo Therapeutics
May 14, 2026
Maintained: Buy
Price Target: $39 → $45
Current: $15.79
Upside: +184.99%
Upstream Bio
May 14, 2026
Maintained: Buy
Price Target: $51 → $50
Current: $8.26
Upside: +505.33%
Erasca
May 12, 2026
Maintained: Buy
Price Target: $28 → $26
Current: $12.47
Upside: +108.50%
Sutro Biopharma
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $29.69
Upside: +68.41%
Revolution Medicines
Apr 24, 2026
Maintained: Buy
Price Target: $140 → $185
Current: $153.00
Upside: +20.92%
Climb Bio
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $11.96
Upside: +50.50%
Spyre Therapeutics
Apr 14, 2026
Maintained: Buy
Price Target: $53 → $84
Current: $72.51
Upside: +15.85%
Apogee Therapeutics
Mar 30, 2026
Maintained: Buy
Price Target: $105 → $110
Current: $77.75
Upside: +41.48%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $10.37
Upside: +150.72%
Jan 29, 2026
Maintained: Buy
Price Target: $30
Current: $17.47
Upside: +71.72%
Jan 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $81.70
Upside: -
Jan 9, 2026
Reiterated: Buy
Price Target: $48
Current: $31.65
Upside: +51.66%
Dec 18, 2025
Initiated Coverage: Hold
Price Target: $18
Current: $21.58
Upside: -16.59%
Mar 21, 2025
Maintained: Buy
Price Target: $4.5
Current: $2.98
Upside: n/a
Mar 20, 2025
Maintained: Buy
Price Target: $36 → $38
Current: $7.73
Upside: n/a
Mar 7, 2025
Maintained: Buy
Price Target: $3.25
Current: $3.81
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $53
Current: $68.65
Upside: n/a
Mar 3, 2025
Maintained: Hold
Price Target: $4.75 → $4.25
Current: $7.89
Upside: n/a
Feb 28, 2025
Maintained: Buy
Price Target: $10
Current: $1.81
Upside: n/a
Feb 28, 2025
Maintained: Hold
Price Target: $7.5 → $6
Current: $4.37
Upside: n/a
Feb 27, 2025
Maintained: Buy
Price Target: $50 → $45
Current: $13.24
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $37 → $38
Current: $50.03
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $105 → $110
Current: $133.69
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $1.07
Upside: n/a
Jan 17, 2025
Maintained: Buy
Price Target: $40 → $15
Current: $11.31
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $11.39
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $10 → $19
Current: $1.36
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $2.31
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $1.87
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $1.66
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $4.78
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $1.47
Upside: n/a
Apr 8, 2024
Maintained: Buy
Price Target: $15
Current: $8.54
Upside: n/a
Mar 14, 2024
Rated: Buy
Price Target: $25 → $26
Current: $31.32
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $2.46
Upside: n/a
Sep 14, 2022
Maintained: Hold
Price Target: $1.5 → $1.75
Current: $2.40
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $6
Current: $26.87
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $15
Current: $1.44
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $10 → $4
Current: $16.91
Upside: n/a
Mar 9, 2022
Maintained: Buy
Price Target: $45 → $36
Current: $12.72
Upside: n/a
Aug 21, 2020
Maintained: Buy
Price Target: $15 → $17
Current: $2.15
Upside: n/a
Apr 7, 2020
Maintained: Buy
Price Target: $28 → $18
Current: $2.44
Upside: n/a